Burkitt Lymphoma – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000

Empower your strategies with our Burkitt Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions.

Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in equatorial Africa, where it’s associated with the Epstein-Barr virus (EBV) infection and frequently affects children. It often presents as tumors in the jaw or facial bones. Sporadic Burkitt lymphoma is found worldwide, and is less associated with EBV but still affects children and adults. It can involve the abdomen, lymph nodes, bone marrow, or other organs. Immunodeficiency-associated Burkitt lymphoma occurs more commonly in individuals with weakened immune systems, such as those with HIV/AIDS or following organ transplantation. Burkitt lymphomas are characterized by rapid growth, often leading to the development of large tumors within a short period. Common symptoms include swelling of the lymph nodes, fever, night sweats, weight loss, and abdominal pain or swelling if organs in the abdomen are affected.

The Burkitt Lymphoma drugs in development market research report provide comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Burkitt Lymphoma
Key Targets
· B Lymphocyte Antigen CD19; B Lymphocyte Antigen CD20; B Cell Receptor CD22; CD3 ; B Cell Antigen Receptor Complex Associated Protein Beta Chain; DNA Topoisomerase II; Interleukin 15 Receptor Subunit Alpha; Myc Proto Oncogene Protein; Tumor Necrosis Factor Receptor Superfamily Member 9; and Tumor Necrosis Factor Receptor Superfamily Member 8
Key Mechanisms of Action
· Interleukin 15 Receptor Subunit Alpha Agonist; DNA Topoisomerase II Inhibitor; CD3 Agonist; Myc Proto Oncogene Protein Inhibitor; Tubulin Inhibitor; Tumor Necrosis Factor Receptor Superfamily Member 10A TNFRSF10A) Agonist; Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist; Oxidized Purine Nucleoside Triphosphate Hydrolase Inhibitor; Probable Global Transcription Activator SNF2L2 Inhibitor; and Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform Inhibitor
Key Routes of Administration
· Intravenous; Parenteral; Oral; Subcutaneous; Intramuscular; and Topical
Key Molecule Types
· Gene-Modified Cell Therapy; Small Molecule; Monoclonal Antibody; Monoclonal Antibody Conjugated; Oligonucleotide; Recombinant Protein; and Fusion Protein
Major Companies
· Gilead Sciences Inc; Bristol-Myers Squibb Co; Wuhan Bio-Raid Biotechnology Co Ltd; Autolus Therapeutics Plc; National Cancer Institute US; National Center for Cardiovascular Research Carlos III; Nektar Therapeutics; Nanchang University Affiliated Hospital One; Mustang Bio Inc; and Miltenyi Biomedicine GmbH

Scope

  • Therapeutics in Development: Covering 70 molecules, with 56 developed by companies and the rest by universities/institutes.
  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
  • Development History: Access the complete research and development history.
  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Burkitt Lymphoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
  • Pipeline Exploration: Explore the detailed Burkitt Lymphoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Burkitt Lymphoma treatments for adaptable decision-making.
  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Achelois BioPharma Inc
August Pi i Sunyer Biomedical Research Institute
Aurigene Oncology Ltd
Autolus Therapeutics Plc
AVM Biotechnology LLC
Beijing zhikangbo Medical Oncology Research Co Ltd
BioCurate Pty Ltd
BioPact Ventures LLC
Biosyngen Pte Ltd
Bristol-Myers Squibb Co
Ceptur Therapeutics Inc
Cornerstone Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
GSK plc
GT Biopharma Inc
Hebei Senlang Biotechnology Co Ltd
Huazhong University of Science & Technology
Iksuda Therapeutics Ltd
Immunitas Therapeutics Inc
JN Biosciences LLC
Karyopharm Therapeutics Inc
Kintor Pharmaceutical Ltd
Meabco AS
Medical College of Wisconsin
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Mustang Bio Inc
Nanchang University Affiliated Hospital One
National Cancer Institute US
National Center for Cardiovascular Research Carlos III
Nektar Therapeutics
Novartis AG
Orano Med LLC
Oxcia AB
Pacylex Pharmaceuticals Inc
PeproMene Bio Inc
Regeneron Pharmaceuticals Inc
Sian Wuhan Medical Technology Co Ltd
Sichuan University
Sorrento Therapeutics Inc
Stanford University
Sutro Biopharma Inc
Swedish Orphan Biovitrum AB
Takeda Pharmaceutical Co Ltd
Third Military Medical University
UNC Lineberger Comprehensive Cancer Center
University of Colorado Denver
University of Texas MD Anderson Cancer Center
UTC Therapeutics Inc
UWELL Biopharma Inc
Vincerx Pharma Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xuzhou Medical University
Y-mAbs Therapeutics Inc
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Burkitt Lymphoma – Drugs In Development, 2024 in real time.

  • Access a live Burkitt Lymphoma – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.